Tracking

How to Track Weight Loss Progress on GLP-1 (Without Getting Obsessed)

GLP-1 Companion · 7 min read

Most people on a GLP-1 medication track weight badly. They weigh too often, react to noise, ignore the metrics that change first, and burn out on the scale by month three. Tracking weight loss well is a small discipline — and it changes how the entire 12-month journey feels.

How Often to Weigh In

Once a week is enough. The clinical trials behind Ozempic, Wegovy, Mounjaro, and Zepbound measured weight at intervals of weeks, not days, because day-to-day fluctuations are dominated by water, sodium, glycogen, the menstrual cycle, and digestive contents. A two-pound swing overnight is almost always one of those — not fat. Weighing daily simply adds anxiety without adding information.

• Pick one day a week — many people use Friday or Saturday morning.
• Same time, ideally first thing in the morning.
• After using the bathroom, before eating or drinking.
• Minimal clothing or naked, so the variable is bodyweight, not your jeans.
• On the same scale, on a hard surface.

Reading a Weight Trend

A weight trend is a line through the noise, not the noise itself. Look at four weeks at a time, not single weeks. On a GLP-1, a normal pattern looks like this: a sharper drop in the first 4–8 weeks (often water and reduced food volume), then a steadier 0.5–1.5% of body weight per week through months 3–6, then a slowing taper toward your dose's effective plateau by months 9–18.

Plateaus of 2–3 weeks within that pattern are normal. Plateaus of 6–8 weeks at a steady dose with consistent habits are worth a conversation with your clinician — that is when dose adjustment, protein audit, or resistance training tend to come up.

The Three Sources of Daily Noise

Knowing why the scale moves day to day is the antidote to reading too much into it.

• Sodium and carbohydrates — a salty restaurant meal can hold 2–4 lb of water for 24–48 hours. Glycogen binds roughly 3g of water per gram stored.
• Menstrual cycle — for menstruating users, weight typically rises 1–4 lb in the luteal phase and drops in the follicular phase. This pattern repeats monthly.
• Digestive contents and constipation — common on GLP-1 due to slowed gastric emptying; can shift the scale 1–3 lb without any change in fat mass.

What to Track Alongside the Scale

The scale measures total body mass. It cannot distinguish fat from muscle, water, or food. Three or four other metrics fix this and consistently move when the scale stalls.

Waist circumference

The single most clinically meaningful measurement you can take at home. Visceral fat — the metabolically harmful fat around abdominal organs — is the first fat to be lost on GLP-1 medications. Waist size often drops during scale plateaus. Measure monthly at the level of your navel, breathing out normally, with a soft tape.

Clothing fit

Keep one pair of pants or one fitted shirt as a benchmark. Try it on once a month. Fit changes are often visible before the scale moves meaningfully — particularly during early visceral-fat loss.

Progress photos

Same lighting, same clothes, same pose (front, side, back), once a month. Most people cannot see their own gradual change in the mirror. The 6-month comparison is the single most motivating data point in the entire GLP-1 journey.

Body composition (when available)

A DEXA scan, a hydrostatic weighing, or a high-quality smart scale gives a fat-vs.-lean breakdown the home scale cannot. Once or twice a year is enough. Pair this with resistance training — preserving and building lean mass on a GLP-1 is one of the highest-impact things you can do for the year-two version of yourself.

Realistic Numbers from the Clinical Trials

A useful anchor for expectations: clinical trials show specific average ranges per medication. Your number will vary based on dose, lifestyle, starting weight, and individual response.

• Ozempic (semaglutide 1–2 mg) — ~6–10% body weight reduction at 12 months.
• Wegovy (semaglutide 2.4 mg) — ~14.9% body weight reduction at 68 weeks (STEP 1 trial).
• Mounjaro / Zepbound (tirzepatide 5/10/15 mg) — ~15%, ~19.5%, ~20.9% at 72 weeks (SURMOUNT-1 trial).

These are averages. Your trajectory may be steeper or flatter, and both are clinically normal. Tracking lets you see your trend against your own baseline rather than against someone else's outcome.

Common Tracking Mistakes

• Weighing daily and reacting to each number.
• Skipping body measurements because "the scale is enough" — it is not.
• Comparing to before-and-after photos of strangers online who are at different doses, ages, and starting points.
• Tracking calorie intake compulsively. On a GLP-1, calories often fall on their own, and over-restricting accelerates lean-mass loss.
• Stopping the log during a plateau — exactly the period when the log is most useful for troubleshooting.

A plateau is not a sign tracking failed. It is the period when tracking shows its highest value, because that is when you and your clinician need data to decide what to change.

A Sustainable Weight-Tracking Routine

A routine that survives 12 months looks roughly like this:

1. Weekly weight, same day, same time. Plot a 4-week trend.
2. Monthly body measurements: waist, hips, chest, thighs, upper arms.
3. Monthly progress photos: front, side, back.
4. Monthly check-in: review the trend, the measurements, and the photos together. The scale rarely lies — but it never tells the full story alone.
5. Quarterly review with your clinician using the consolidated record.

Key Takeaways

• Weigh once a week, same time, same conditions. Daily weighing adds noise without adding signal.
• Read trends in 4-week windows. Plateaus of 2–3 weeks are normal.
• Pair the scale with waist measurement, clothing fit, and monthly progress photos.
• Sodium, the menstrual cycle, and digestive contents explain most short-term scale swings.
• Tracking matters most during plateaus, not during the easy weeks.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.